This review provides a compendium of retrievable results of genotoxicity and carcinogenicity assays performed on marketed gastrointestinal drugs. Of the 71 drugs considered, 38 (53.5%) do not have retrievable data, whereas the other 33 (46.5%) have at least one genotoxicity or carcinogenicity test result. Of these 33 drugs, 15 tested positive in at least one genotoxicity assay and 13 in at least one carcinogenicity assay; 8 of them gave a positive response in both at least one genotoxicity assay and at least one carcinogenicity assay. Concerning the predictivity of genetic toxicology findings for the result(s) of long-term carcinogenesis assays, of 21 drugs with both genotoxicity and carcinogenicity data: 6 (28.6%) are neither genotoxic nor carcinogenic, 2 (9.5%) tested positive in at least one genotoxicity assay but were non-carcinogenic, 5 (23.8%) tested negative in genotoxicity assays but were carcinogenic and 8 (38.1%) gave a positive response in at least one genotoxicity assay and in at least one carcinogenicity assay. Only 12 (16.9%) of the 71 drugs examined have all data required by present guidelines for testing of pharmaceuticals, but a large fraction of them were developed and marketed prior the present regulatory climate.
Introduction
Drugs for the treatment of gastrointestinal disorders are used by numberless patients for long periods of time or frequently in an intermittent manner. Among the various adverse reactions that these drugs may cause, the occurrence of a genotoxic and/or carcinogenic effect cannot be excluded, and it should be considered in the evaluation of the benefit:risk ratio. Therefore, we deemed useful to examine to what extent the drugs of this family underwent testing for their genotoxic and carcinogenic activity. Present guidelines for genotoxicity testing of pharmaceutical (1-3) indicate a standard test battery that consists of: (i) a test for gene mutation in bacteria, (ii) an in vitro test with cytogenetic evaluation of chromosomal damage with mammalian cells or an in vitro mouse lymphoma tk assay that can detect both gene mutation and chromosomal damage and (iii) an in vivo test for chromosomal damage using rodent haematopoietic cells. For a compound that induces a biologically relevant positive result in one or more in vitro tests, a further in vivo test using a tissue other than the bone marrow/ peripheral blood should be done. Guidelines for carcinogenicity testing of pharmaceuticals (4, 5) indicate that a long-term carcinogenicity study plus a short-or medium-term in vivo system should be performed for all pharmaceuticals whose expected clinical use is continuous for at least 6 months as well as for pharmaceuticals used frequently in an intermittent manner in the treatment of chronic recurrent conditions. In the absence of clear evidence favouring one species, the rat should be selected. In long-term carcinogenicity assays, the highest dose should be at least . 25 -fold, on a milligram per square meter basis, than the maximum recommended human daily dose or represent a 25-fold ratio of rodent to human area under the curve. The maximum tolerated dose (MTD) or a limit dose of 2000 mg/kg can be used as alternatives.
From the 2007 edition of the Martindale-The Complete Drug Reference (6) , it can be inferred that 71 gastrointestinal drugs of long-term or intermittent frequent use are on the market, and the majority of them are used in several countries. In a review of Snyder and Green (7), on the genotoxicity of marketed pharmaceuticals, there are only 15 gastrointestinal drugs, but no data are reported for 3 of them and for some of the remaining, the information is quite limited. The International Agency for Research on Cancer (8) in the 91 volumes of International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans published in the years from 1972 to 2007 examined more than 200 drugs, but these included only three gastrointestinal drugs: danthron and phenolphthalein classified as possibly carcinogenic to humans (Group 2B) and cimetidine considered nonclassifiable as to its carcinogenicity in humans (Group 3). These premises suggest that in prescribing most gastrointestinal drugs, the evaluation of the benefit:genotoxic-carcinogenic risk ratio is impossible. Therefore, we deemed useful to assess whether data allowing a more extensive information can be retrieved.
This review is a compendium of all the genotoxicity and carcinogenicity data that have been found in an extensive search. This search was conducted primarily in peer-reviewed journals using Medline, Toxline and the Registry of Toxic Effects of Chemicals Substances (9) . Additional unpublished data were obtained from the following Websites: http:/www .toxnet.nlm.nih.gov, http://www.ntp.server.niehs.nih.gov,http: //www.potency.berkeley.edu, http://www.fda.gov/cder and http://www.scirus.com. Concerning data that are not published in peer-reviewed journals, in some cases, the tests were conducted under the oversight of authoritative bodies, such as the U.S. National Toxicology Program; in the other cases, the genotoxicity and carcinogenicity data are those reported by the Physician's Desk Reference (10) or in the final package insert approved by the Center for Drug Evaluation and Research of the Food and Drug Administration. Unfortunately, this additional unpublished information if often incomplete; in particular, the results of genotoxicity assays are usually reported without any information of the doses that have been tested. Moreover, often no information is given whether the in vitro genotoxicity assays were performed in both the presence and the absence of an exogenous metabolic system; in these cases, in the absence of a specific indication, the result is reported in the tables as obtained in both these experimental conditions.
Results of genotoxicity and carcinogenicity assays
Information on genotoxic and/or carcinogenic effects of gastrointestinal drugs was retrieved for only 33 (46.5%) of the 71 marketed pharmaceuticals considered (Table I) . Only 12 drugs can be considered, on the basis of retrieved data, as tested in substantial agreement with the indications of the present guidelines on genotoxicity and carcinogenicity testing of pharmaceuticals. Of these 12 drugs: alosetron and mesalazine gave negative responses in all genotoxicity assays and were not carcinogenic in rodents; lubiprostone, nizatidine, olsalazine and tegaserod tested negative in genotoxicity assays but gave at least one positive result in carcinogenesis assays; lansoprazole, omeprazole, pantoprazole, phenolphthalein, rabeprazole and sulfasalazine gave positive response(s) in both genotoxicity and carcinogenicity assays. Some additional drugs were tested for both genotoxicity and carcinogenicity but not as recommended by present guidelines: cisapride, famotidine, hyoscine and ranitidine gave negative responses in both genotoxicity and carcinogenicity assays; balsalazide and dronabinol tested positive in one and three genotoxicity assays, respectively, but were non-carcinogenic; bisacodyl tested negative in genotoxicity assays but was carcinogenic in rats; cimetidine and danthron gave positive responses in both genotoxicity and carcinogenicity assays. Of seven drugs, we retrieved only results of genotoxicity assays: aloe-emodin, casanthrol, esomeprazole, metoclopramide and propanteline gave one or more than one positive response; bismuth salicylate and pirenzepine gave a single negative and a single inconclusive responses, respectively. Of five drugs-aluminium hydroxide, enoxolone, irsogladine, loperamide and sucralfatewere retrieved only negative results of carcinogenesis assays.
Of 38 (53.5%) gastrointestinal drugs, neither results of genotoxicity assays nor results of carcinogenicity assays were retrieved.
Discussion
The present survey was performed to assess to what extent gastrointestinal drugs have been tested for their genotoxic and carcinogenic activity. It cannot be excluded that additional published and unpublished results of difficult retrieval exist; notwithstanding, we deem that information provided by this review is sufficient to give an overall prespective of the present knowledge and to allow some considerations about the possibility for the scientific community of evaluating the genotoxic-carcinogenic risk to humans and the corresponding benefit/risk ratio of the 71 gastrointestinal pharmaceuticals examined. Table II indicates the number of drugs which underwent testing in the various types of genotoxicity assays: 26 drugs underwent testing for bacterial mutagenicity, 14 for gene mutation in mammalian cells, 21 for in vitro cytogenetics, 23 for in vivo cytogenetics, 15 for DNA damage and/or DNA repair synthesis and 11 in other types of genotoxicity assays. Twelve drugs were tested for genotoxicity in human cells. Concerning carcinogenicity, 22 drugs were tested in mice and 25 in rats, but it should be considered that 15 drugs gave negative responses at doses to various extent lower than that recommended by present guidelines, i.e. lower than 25-fold the maximum recommended human daily dose on a milligrams per square meter basis. However, it should be considered that four of these drugs were tested at the MTD of 2000 or 2500 mg/kg. Table III provides for each type of assay the number of drugs with positive, negative and discordant results. It is worth noting that the majority of gastrointestinal drugs tested negative in the various types of genotoxicity assays; the fraction of those giving a positive response being to some extent higher in gene mutation in mammalian cells and in in vitro cytogenetics assays. Some drugs with substantial chemical similarities allow the following considerations with respect to the relationship between chemical moieties and genotoxicity. All the prazoles (esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole) cause chromosomal damage. Of the four salazines, balsalazide and sulfasalazine gave same evidence of genotoxicity, whereas mesalazine and olsalazine tested negative in genotoxicity assays. Of the four histamine analogues H2-receptor antagonists, famotidine, nizatidine and ranitidine tested negative in genotoxicity assays, whereas cimetidine gave some evidence of DNA damage in primary rat hepatocytes.
With Table I ) were carcinogenic in rats. Of the five drugs carcinogenic in both mice and rats, four were carcinogenic in different organs. Two drugs (22, 25) gave discordant results in mice and three (23, 24, 29) in rats, but with the exception of omeprazole for the other four drugs, this discordance is the result of difference between the two sexes. Eight drugs (5,8,19,22,23,24,29,33 of Table I ) gave discordant results in the two species. However, of six drugs carcinogenic in rats and non-carcinogenic in mice, olsalazine and rabeprazole gave a positive response only in one sex and nizatidine was carcinogenic only in female mice and non-carcinogenic in rats.
An analysis of the correlation among the results of the various types of genotoxicity assays is shown in Table IV . The percentage of concordant results ranges from a maximum of 90% between bacterial mutagenicity and DNA lesions to a minimum of 66.7% between DNA lesions and in vitro cytogenetics, bacterial mutagenicity and in vitro cytogenetics and DNA lesions and gene mutation. The occurrence of discordance between the results of genotoxicity assays has been previously reported. According to Ishidate et al. (57) , the 90% of substances negative in the Ames test were positive in the chromosomal aberrations assay, and only 59% of clastogens were also positive in the Ames test. Discordance between the results of the various in vitro and in vivo genotoxicity assays is not surprising due to the different sensitivity of the systems for the detection of the different types of mechanism of genetic damage.
An analysis of the correlation between the results of the various types of genotoxicity assays and the results of carcinogenicity assays is reported in Table V . The drugs included in this analysis are only those that in the genotoxicity assay considered gave only positive result(s) or only negative or inconclusive result(s) and in carcinogenesis assays induced tumour development in at least one sex of mice or rats or gave only negative or inconclusive result(s). It is evident the occurrence of discordant results in all the 15 couples of assays considered, their percentage ranging from a maximum of 45.5% between DNA lesions and carcinogenicity in mice to a minimum of 23.1% between both in vitro and in vivo cytogenetics and carcinogenicity in mice. If carcinogenicity in both mice and rats is considered, the percentage of discordant results ranges from the 37.5% in the case of DNA lesions to 0 in the case of gene mutation in mammalian cells but it should be considered that in the last case, the absence of discordant results concerns only three drugs. As a whole, these values are in many cases based on low numbers and therefore useful for a qualitative but not for a quantitative comparison with other published works. A substantially similar correlation between the results of the various types of genotoxicity assays and the results of carcinogenicity assays was previously found by our group for analgesics, anti-inflammatory drugs and antipyretics (58) and for benzodiazepines (59) , as well as by studies of other authors (57, (60) (61) (62) . Collectively the merits of genotoxicity assays for detecting carcinogens are clear. Moreover, it should be considered that carcinogenicity is not the only important consequence of genotoxicity in terms of human diseases since the occurrence of in vivo genotoxic effects is likely to be important in aetiology of diseases other than cancer, e.g. teratogenesis, infertility and in a proportion of cases probably also Alzheimer's disease, atherosclerosis, autoimmune diseases, myopathies and slow neuronal prionbased diseases. However, it should be considered that recent data (63, 64) have shown that in vitro assays commonly employed in regulatory screening strategies are often positive for chemicals considered not to present a significant genotoxic or carcinogenic risk in vivo, the rate of positive responses for non-carcinogens becoming exceptionally high when test batteries are employed. Moreover, also a positive result in an in vivo genotoxicity assay does not necessarily support the conclusion of a genotoxic activity. According to Tweats et al. (65) , there is growing body of evidence that compound-related disturbances in the physiology of rodents can result in increases Long-term carcinogenesis assay, rats À (Â171) 180 mg/kg/day (10, 17) Gastrointestinal drugs without retrievable data: aceglutamide aluminium, aclantonium napadisilate, alexitol sodium, alizapride, almagate, almasilate, alverine, benexate, bisoxatin, bromopride, butropium, buzepide metiodide, cetraxate, ciclonium bromide, cimetropium bromide, cinitapride, clebopride, clidinium bromide, difenidol, dicycloverine, diphenoxylate, dosmalfate, ecabet, hyoscyamine, isopropamide, itopride, lafutidine, magaldrate, mebeverine, mosapride, plaunotol, proglumide, ranitidine bismuth citrate, roxatidine, sodium picosulfate, sofalcone, teprenone and troxipide. þ, Positive; (þ), weakly positive; À, negative; ?, equivocal; NT, not tested; without e.m.s., without exogenous metabolic system; with e.m.s., with exogenous metabolic system. LED, lowest effective dose; HID, highest ineffective dose; NR, not reported; po, oral; ip, intraperitoneal. The number in parentheses indicates the ratio [high animal dose (mg/m 2 )/maximum recommended human dose (mg/m
2 )].
in micronucleated cells in the bone marrow that are not related to the intrinsic genotoxicity of the compound under test. In contrast, it has been shown that there are carcinogens which gave negative or equivocal results in the in vivo micronucleus test. Finally, it should be considered that the result of an assay is dependent on the experimental procedure employed and on the interpretation of the data obtained, which may be different in different laboratories and may evolve with time. Finally, Table VI indicates, using the same criteria of inclusion indicated for Table V, the percentages of gastrointestinal drugs that, according to results obtained in the various types of genotoxicity assays, may be classified as nongenotoxic non-carcinogens, genotoxic non-carcinogens, nongenotoxic carcinogens and genotoxic carcinogens. These percentages depend on the genotoxicity assay considered. For instance, are classified as non-genotoxic non-carcinogens the 44 .4% of drugs that tested negative in bacterial mutagenicity assays and the 18.2% of those that tested negative in gene mutation assays and as genotoxic carcinogens the 23.0% of drugs that tested positive in in vitro cytogenetic assays and the 5.6% of those that tested positive in bacterial mutagenicity assays. If we prudently presume that a drug might be considered genotoxic if tested positive in at least one genotoxicity assay and carcinogenic if tested positive in at least one sex of mice or rats, of the 21 drugs with both genotoxicity and carcinogenicity assays 8 (8,10,17,24,25,26,29,32 of Table I ) might be classified as genotoxic carcinogens even if they provided in genotoxicity assays contrasting results. Five drugs (5,19,22,23,33 of Table I ) might be considered nongenotoxic carcinogens. In a quantitative risk assessment, the capability of distinguishing between genotoxic and nongenotoxic carcinogens is important for the prediction of the dose-response curve and for the extrapolation of experimental data to relevant levels of human exposure. While threshold models are valid for non-genotoxic carcinogens, a no-effect level usually cannot be expected for genotoxic carcinogens, although this view has been challenged increasingly in recent times. According to IARC (66) , an agent is classified as probably carcinogenic to humans (Group 2A) when there is limited evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals. Exceptionally, an agent may be classified in this category solely on the basis of limited evidence of carcinogenicity in humans or sufficient evidence of carcinogenicity in experimental animals strengthened by supporting evidence from relevant genotoxicity data. An agent is classified as possibly carcinogenic to humans (Group 2B) when there is limited evidence in humans in the absence of sufficient evidence in experimental animals. It may be also classified in this category when there is inadequate evidence of carcinogenicity in humans or when human data are non-existent, but there is sufficient evidence of carcinogenicity Drugs considered as positive are those that gave only positive results. Drugs considered as negative are those that gave only negative or inconclusive results. Discordant indicates the number of drugs that gave both positive and negative or inconclusive results in genotoxicity assays and in carcinogenicity assays performed in the same species or were carcinogenic to mice but not to rats and vice versa. Numbers in parentheses are those of drugs of Table I . in experimental animals. In some instances, an agent for which there is inadequate evidence or no data in humans but limited evidence of carcinogenicity in experimental animals together with supporting evidence from other relevant data may be placed in Group 2B. On the basis of these indications, four drugs may be considered as possibly carcinogenic to humans: danthron and phenolphthalein already classified by IARC in Group 2B and tentatively lansoprazole and pantoprazole. All the other drugs, on the basis of retrieved data, should be considered not classifiable as to their carcinogenicity to humans (Group 3); cimetidine has been already classified by IARC in this group. Finally, it should be considered that genotoxic carcinogenic effects might be produced in humans by the N-nitroso The data indicate the number of non-carcinogens and carcinogens examined in each genotoxicity assay that tested negative (non-genotoxic) and positive (genotoxic) in the same assay. In this analysis were considered as non-carcinogens those drugs that did not increase tumour incidence in mice and/or rats of both sexes and as carcinogens those drugs that increased tumour incidence in at least one sex of mice or rats. Only the drugs that gave a single negative or concordant negative results and the drugs that gave a single positive or concordant positive results in the indicated genotoxicity assay were considered non-genotoxic and genotoxic, respectively, and were included in this analysis. Numbers in parentheses are those of drugs of Table 1 . compounds formed in the gastric environment by the reaction with nitrite of gastrointestinal drugs which are theoretically nitrosatable amine drugs (67) . In this respect, it should be considered that cimetidine, metoclopramide and ranitidine have been found to form N-nitroso compounds by reacting with nitrite. Moreover, genotoxic effects have been found to be produced by the nitrosation mixture of cimetidine, famotidine, metoclopramide and ranitidine.
In conclusion, it is evident that the information provided by this survey on the genotoxic and carcinogenic activity of gastrointestinal drugs suggest that for the large majority of the 71 marketed pharmaceuticals considered, available data are inadequate for a reliable assessment of the potential genotoxic and carcinogenic risk to humans. Efforts to develop and refine methods for genotoxicity and carcinogenicity testing of pharmaceuticals started $20 years ago, and present guidelines were published in 1996-97 (1) (2) (3) (4) (5) . This explains why for several gastrointestinal drugs results of genotoxicity and carcinogenicity assays recommended by present guidelines were not retrieved. A problem that arises is the need of retrospective testing of old drugs. Probably, a balance should be found between the view that these drugs should be brought up to current standards and the view that no additional testing is needed. In our opinion, no additional testing is needed when the safety of a drug long-term use in humans has been ascertained by epidemiological studies. In this case, it may be considered that safety in humans is more important than previous data from genotoxicity or carcinogenicity assays, their relevance to humans being dubious when a poor correlation exists between rat and mouse carcinogenicity and between the results of these assays and those of genotoxicity assays. On the contrary, testing according to present guidelines should be done when safety of a long-term use in humans is doubtful or not ascertained, and some evidence suggests genotoxicity and carcinogenic activity in animals.
